FEBRUARY 3 FEB 3
2018
8:00 AM - 4:30 PM
SATURDAY SAT

Stanford's Review of the 59th Annual American Society of Hematology Meeting 2018

Ritz –Carlton, Half Moon Bay, CA

A Continuing Medical Education Conference Presented by the Division of Hematology at the Stanford University School of Medicine.

Online registration is now closed

On-site registration is available.

Statement of Need

This CME event led by the Stanford Division of Hematology seeks to fulfill the need of practicing Hematologists/Oncologists, Nurse Practitioners, Physician Assistants, Pharmacists and Allied Health Care Practitioners in the academic and community settings to increase the fund of knowledge in malignant and benign hematology by reviewing the latest data presented at the 59th Annual American Society of Hematology Meeting. The goal of the symposium is to enhance both competence and performance of practitioners in the diagnosis, prognostication, and treatment of patients with malignant and non-malignant hematologic disorders.

Target Audience

This conference is for hematologists, oncologists, nurse practitioners, physician assistants, nurses and pharmacists who care for patients with malignant and benign hematologic diseases.

Learning Objectives

At the conclusion of this activity, learners will be able to:

Review and evaluate data from the most recent clinical trials and develop strategies to:

  1. Evaluate new chemotherapy/biologic regimens for different subpopulations of acute myeloid leukemia patients based on clinical and genetic prognostic factors and determine how to apply them to treatment decisions
  2. Apply strategies to optimally utilize JAK inhibition and other novel agents in patients with Myelofibrosis, polycythemia vera (PV), and other relevant myeloproliferative neoplasms (MPNs) and use prognostic models to risk stratify MPN patients for therapy
  3. Analyze the role of new biologics for advanced systemic mastocytosis
  4. Evaluate optimal sequencing and combinations of novel biologics for chronic lymphocytic leukemia (CLL), and the current role of testing for molecular abnormalities and MRD testing
  5. Incorporate available therapeutic options for patients with low- or high-risk myelodysplastic syndromes, including those who are relapsed/refractory to hypomethylating agents and utilize the IPSS-R prognostic scoring system and new mutation data to classify patients for treatment
  6. Determine the best combination regimens and novel agents for relevant populations of newly diagnosed and relapsed/refractory myeloma patients, including transplant eligible vs. ineligible, and new antibody therapies, as well as the role for MRD testing
  7. Evaluate the results of phase II/III trials in Hodgkin and non-Hodgkin lymphomas
  8. Determine appropriate use of emerging novel therapies for patients with hemophilia
  9. Evaluate new treatment indications for direct oral anticoagulants for patients with non-
    malignant hematology
  10. Review new therapeutic directions in sickle cell disease and disorders of iron homeostasis

 

Course Directors

Jason Gotlib, MD, MS

Professor of Medicine
Division of Hematology

Michaela Liedtke, MD

Associate Professor of Medicine
Division of Hematology

A Continuing Medical Education Activity

Presented by the Department of Medicine at the Stanford University School of Medicine.

Sponsored by the Stanford University School of Medicine


Conference Contact

For conference related questions please contact

Debbie Aube
CME Conference Coordinator
(650) 724-5318
debbie.aube@stanford.edu

For general questions, please send us an email or call us
stanfordcme@stanford.edu
(650) 497-8554

 

Mailing List

New activities are added regularly.  Join our mailing list to receive notifications about activities of interest to you.